ScreenerHero
ABNXABIONYX Pharma SA
EPA · FR · Healthcare · Biotechnology · abionyx.com
1.954EUR-1.31%Mkt Cap: 89.89M $P/E: —

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activiti…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap89.89M $
Enterprise Value76.73M $
Revenue (TTM)4.42M $
Gross Profit580.43K $
Net Income (TTM)-6.03M $
Revenue/Share0.1261 USD
Last Price1.954 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees49
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012616852
Valuation
P/E (Trailing)—
P/E (Forward)-6.73
PEG—
EV/EBITDA-13.02
EV/Revenue17.37
P/S20.75
P/B15.56
EPS (TTM)-0.16
EPS (Forward)-0.30
52W Range
1.8204% of range5.290
52W High5.290 EUR
52W Low1.820 EUR
Profitability
Gross Margin13.14%
Oper. Margin-165.02%
EBITDA Margin-133.47%
Profit Margin-136.60%
ROE-123.01%
ROA-42.32%
Growth
Revenue Growth-11.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.19M $
CapEx (TTM)263.04K $
FCF Margin-7.07%
FCF Yield-0.35%
Net Debt308.70K $
Net Debt/EBITDA-0.05
Balance Sheet
Debt/Equity0.84
Current Ratio1.06
Quick Ratio0.99
Book Value/Sh0.1280 EUR
Cash/Share0.1000 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)10.50 EUR
Upside (mean)+437.4%
Target Range10.00 EUR – 11.00 EUR
€10.00+437.4% to mean€11.00
# Analysts2
Ownership
Shares Out.42.32M
Float19.75M
Insiders29.97%
Institutions3.74%
Technical
SMA 502.038 (-4.1%)
SMA 2003.188 (-38.7%)
Beta0.45
S&P 52W Chg18.16%
Avg Vol (30d)116.33K
Avg Vol (10d)179.47K
Technical Indicators
RSI (14)50.2
MACD-0.0226
MACD Signal-0.0456
MACD Hist.+0.0230
BB Upper2.012 EUR
BB Middle1.927 EUR
BB Lower1.843 EUR
BB Width8.73%
ATR (14)0.0906 EUR
Vol Ratio (20d)1.28x